Niagen Bioscience, Inc. Earnings Per Share Disclosure
| Year Ended December 31, | |||||||||||
| (In thousands, except per share data) | 2025 | 2024 | |||||||||
| Numerator: | |||||||||||
| Net income | 17,382 | 8,550 | |||||||||
| Denominator: | |||||||||||
| Weighted average common shares outstanding for basic earnings per share (1) | 79,178 | 75,929 | |||||||||
| Plus: incremental shares from assumed exercise of options and assumed vesting of restricted stock (2) | 6,258 | 2,196 | |||||||||
| Adjusted weighted average common shares outstanding for diluted earnings per share | 85,436 | 78,125 | |||||||||
| Earnings Per Share: | |||||||||||
| Basic net income per common share | $ | 0.22 | $ | 0.11 | |||||||
| Diluted net income per common share | $ | 0.20 | $ | 0.11 | |||||||
| Year Ended December 31, | |||||||||||
| (In thousands) | 2025 | 2024 | |||||||||
| Stock options | 1,682 | 4,087 | |||||||||
Want the next Niagen Bioscience, Inc. earnings per share disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Niagen Bioscience, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 4, 2026 | Showing above |
| 2024 | Mar 4, 2025 | |
| 2023 | Mar 6, 2024 | |
| 2022 | Mar 8, 2023 | |
| 2021 | Mar 14, 2022 | |
| 2019 | Mar 10, 2020 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.